[go: up one dir, main page]

CL2013003305A1 - Uso del compuesto 4-fenil-(4-metilsulfinil)-5-(4-piridil)-1h-imidazol, inhibidores de map quinasa p38, para tratar adherencias; compuestos derivados de 4-fenil-(4-metilsulfinilfenil)-5-(4-piridil)-1h-imodazol; y composiciones farmacéuticas que los comprenden. - Google Patents

Uso del compuesto 4-fenil-(4-metilsulfinil)-5-(4-piridil)-1h-imidazol, inhibidores de map quinasa p38, para tratar adherencias; compuestos derivados de 4-fenil-(4-metilsulfinilfenil)-5-(4-piridil)-1h-imodazol; y composiciones farmacéuticas que los comprenden.

Info

Publication number
CL2013003305A1
CL2013003305A1 CL2013003305A CL2013003305A CL2013003305A1 CL 2013003305 A1 CL2013003305 A1 CL 2013003305A1 CL 2013003305 A CL2013003305 A CL 2013003305A CL 2013003305 A CL2013003305 A CL 2013003305A CL 2013003305 A1 CL2013003305 A1 CL 2013003305A1
Authority
CL
Chile
Prior art keywords
pyridyl
phenyl
pharmaceutical compositions
imodazole
methylsulfinylphenyl
Prior art date
Application number
CL2013003305A
Other languages
English (en)
Inventor
Mikhail Gennadievich Shurygin
Irina Aleksandrovna Shurygina
Original Assignee
Pharmasyntez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2011119848/15A external-priority patent/RU2011119848A/ru
Application filed by Pharmasyntez filed Critical Pharmasyntez
Publication of CL2013003305A1 publication Critical patent/CL2013003305A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/0206Polyalkylene(poly)amines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • C08G73/0605Polycondensates containing five-membered rings, not condensed with other rings, with nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L79/00Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
    • C08L79/04Polycondensates having nitrogen-containing heterocyclic rings in the main chain; Polyhydrazides; Polyamide acids or similar polyimide precursors
    • C08L79/06Polyhydrazides; Polytriazoles; Polyamino-triazoles; Polyoxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCIÓN SE REFIERE AL CAMPO DE LA FARMACIA, MEDICINA CLÍNICA Y EXPERIMENTAL Y LA MEDICINA VETERINARIA, Y EN PARTICULAR, A NUEVOS COMPUESTOS INHIBITORIOS DE UNA P38 MAP QUINASA CON UNA ESTRUCTURA DEL TIPO (I) - (VII) QUE PUEDEN SER UTILIZADOS PARA EL TRATAMIENTO O LA PROFILAXIS DE ADHERENCIA. LA INVENCIÓN DA A CONOCER COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN UNA CANTIDAD EFICAZ DE LA SUSTANCIA SB203580 O UNO DE LOS COMPUESTOS DEL TIPO (I) - (VII) O UNA COMBINACIÓN DE LOS MISMOS Y UN VEHÍCULO FARMACÉU
CL2013003305A 2011-05-17 2013-11-18 Uso del compuesto 4-fenil-(4-metilsulfinil)-5-(4-piridil)-1h-imidazol, inhibidores de map quinasa p38, para tratar adherencias; compuestos derivados de 4-fenil-(4-metilsulfinilfenil)-5-(4-piridil)-1h-imodazol; y composiciones farmacéuticas que los comprenden. CL2013003305A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011119848/15A RU2011119848A (ru) 2011-05-17 2011-05-17 Способ профилактики спайкообразования
RU2011153043 2011-12-26

Publications (1)

Publication Number Publication Date
CL2013003305A1 true CL2013003305A1 (es) 2014-07-18

Family

ID=47176372

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003305A CL2013003305A1 (es) 2011-05-17 2013-11-18 Uso del compuesto 4-fenil-(4-metilsulfinil)-5-(4-piridil)-1h-imidazol, inhibidores de map quinasa p38, para tratar adherencias; compuestos derivados de 4-fenil-(4-metilsulfinilfenil)-5-(4-piridil)-1h-imodazol; y composiciones farmacéuticas que los comprenden.

Country Status (31)

Country Link
US (2) US10172952B2 (es)
EP (2) EP2716684B1 (es)
JP (2) JP5936683B2 (es)
KR (2) KR20170034950A (es)
CN (1) CN103534293B (es)
AP (1) AP3694A (es)
AU (3) AU2012257347A1 (es)
BR (1) BR112013029616B1 (es)
CA (1) CA2836268C (es)
CL (1) CL2013003305A1 (es)
CO (1) CO6801779A2 (es)
CR (1) CR20130600A (es)
CY (1) CY1122190T1 (es)
DK (1) DK2716684T3 (es)
DO (1) DOP2013000266A (es)
EA (1) EA025493B1 (es)
GE (1) GEP201706614B (es)
IL (1) IL229423B (es)
LT (1) LT2716684T (es)
MA (1) MA35189B1 (es)
MX (2) MX369019B (es)
NI (1) NI201300124A (es)
PE (1) PE20141161A1 (es)
PH (1) PH12013502381B1 (es)
PL (1) PL2716684T3 (es)
RS (1) RS59382B1 (es)
RU (1) RU2582975C2 (es)
SI (1) SI2716684T1 (es)
SV (1) SV2013004582A (es)
WO (1) WO2012156938A1 (es)
ZA (1) ZA201308542B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025493B1 (ru) * 2011-05-17 2016-12-30 Акционерное Общество "Фармасинтез" Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса
RU2745965C1 (ru) * 2020-11-23 2021-04-05 Галина Анатольевна Пучкина Способ профилактики послеоперационного спаечного процесса органов малого таза
RU2749435C1 (ru) * 2020-11-27 2021-06-10 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Способ лечения энтеральной недостаточности при воспалительных и травматических повреждениях брюшины

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
WO1997005878A1 (en) * 1995-08-10 1997-02-20 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5894971A (en) 1998-02-02 1999-04-20 Huang; Te Chien Tool holder for attaching tools to user's hand
US6521223B1 (en) 2000-02-14 2003-02-18 Genzyme Corporation Single phase gels for the prevention of adhesions
CA2419633C (en) * 2000-08-17 2011-05-10 Pfizer Inc. Substituted imidazoles as tafia inhibitors
AU2003249977A1 (en) * 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US7728013B2 (en) * 2005-05-10 2010-06-01 Intermune, Inc. Method of modulating stress-activated protein kinase system
CN101443044A (zh) * 2005-09-22 2009-05-27 哈达斯特医学研究服务与开发有限公司 治疗活性化合物的葡聚糖和阿拉伯半乳聚糖结合物
CN101535308A (zh) * 2006-11-09 2009-09-16 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的取代的6-苯基-吡啶并[2,3-d]嘧啶-7-酮衍生物及其使用方法
JP5530635B2 (ja) * 2007-02-14 2014-06-25 独立行政法人科学技術振興機構 腸管癒着抑制剤
WO2009028965A1 (en) * 2007-08-28 2009-03-05 Theodore Athanasiadis Surgical hydrogel
RU2363476C1 (ru) 2007-12-20 2009-08-10 Марина Сергеевна Гомон Способ профилактики образования послеоперационных спаек
WO2009103821A2 (de) * 2008-02-23 2009-08-27 Virologik Gmbh Mittel zur behandlung von virusinfektionen
US8205286B1 (en) 2008-10-21 2012-06-26 Milagros Diaz Pillow for female breasts
EA025493B1 (ru) * 2011-05-17 2016-12-30 Акционерное Общество "Фармасинтез" Соединения, фармацевтические композиции и способ профилактики и лечения спаечного процесса
US20140259423A1 (en) 2013-03-13 2014-09-18 Evan Joseph FALCK Helmet Pillow

Also Published As

Publication number Publication date
RU2013155582A (ru) 2015-06-27
HK1189012A1 (en) 2014-05-23
IL229423B (en) 2018-04-30
KR20170034950A (ko) 2017-03-29
NZ618882A (en) 2016-03-31
IL229423A0 (en) 2014-01-30
EP2716684A4 (en) 2015-07-15
ZA201308542B (en) 2014-07-30
EP2716684A1 (en) 2014-04-09
EP3569636A1 (en) 2019-11-20
EP2716684B1 (en) 2019-06-26
WO2012156938A1 (ru) 2012-11-22
KR20140074259A (ko) 2014-06-17
AU2012257347A1 (en) 2014-01-09
SI2716684T1 (sl) 2019-11-29
JP2014515057A (ja) 2014-06-26
PL2716684T3 (pl) 2020-01-31
CO6801779A2 (es) 2013-11-29
MX382507B (es) 2025-03-13
PE20141161A1 (es) 2014-10-01
US10172952B2 (en) 2019-01-08
NI201300124A (es) 2014-02-25
GEP201706614B (en) 2017-02-10
AU2015213303A1 (en) 2015-09-03
CR20130600A (es) 2014-04-29
AU2017221883B2 (en) 2019-06-20
CY1122190T1 (el) 2020-11-25
MX369019B (es) 2019-10-24
RU2582975C2 (ru) 2016-04-27
LT2716684T (lt) 2019-09-25
MX2019011386A (es) 2019-10-30
SV2013004582A (es) 2018-11-12
CA2836268A1 (en) 2012-11-22
PH12013502381A1 (en) 2014-02-10
DOP2013000266A (es) 2014-06-01
BR112013029616A2 (pt) 2020-08-25
PH12013502381B1 (en) 2021-03-26
EA201301275A1 (ru) 2014-03-31
US20190125886A1 (en) 2019-05-02
AU2017221883A1 (en) 2017-09-28
AP3694A (en) 2016-04-30
RS59382B1 (sr) 2019-11-29
MX2013013409A (es) 2014-07-11
CN103534293A (zh) 2014-01-22
DK2716684T3 (da) 2019-09-30
US20140079663A1 (en) 2014-03-20
EA025493B1 (ru) 2016-12-30
CN103534293B (zh) 2015-10-21
JP5936683B2 (ja) 2016-06-22
JP2016175931A (ja) 2016-10-06
BR112013029616B1 (pt) 2022-09-20
AP2013007258A0 (en) 2013-11-30
CA2836268C (en) 2018-07-03
MA35189B1 (fr) 2014-06-02
US10493164B2 (en) 2019-12-03

Similar Documents

Publication Publication Date Title
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
SV2010003776A (es) Derivados de pirimidina como inhibidores de cinasa
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
MX395342B (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
MX2017012613A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
MX2016002589A (es) Composicion farmaceutica que contiene compuesto de pirimidina como ingrediente activo.
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
ECSP109965A (es) Imidazoles fusionados para el tratamiento del cancer
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
MY173126A (en) Arylquinazolines
HUE060743T2 (hu) Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére
EA201591781A1 (ru) Химические соединения
CL2011000195A1 (es) Compuestos derivados de 5-alquinil-pirimidina, inhibidores de quinasas; composiciones farmaceuticas que comprenden a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
BR112015029462A2 (pt) Inibidores de quinase
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201492069A1 (ru) Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)